Diabetes Mellitus: A Fundamental and Clinical Text
3rd Edition
© 2004 Lippincott Williams & Wilkins
←↑→
R
RAAS
1504–1507
Rabbits
rubella virus
diabetes mellitus
582
Rabson-Mendenhall syndrome
1013
Race
type 2 diabetes mellitus
1077
1078
Racial groups
type 2 diabetes mellitus
786
787
Radiculopathy
1337
Radioactive glucose tracers
811
Radioimmunoassays
474
Raf
Ras activation
274–277
RAGE
1317
1444
Randle cycle
reverse
994–996
Rapamycin
290
702
715
oral ulcerations
728
P70 S6 kinase/EIF-4# binding protein (PHAS01) mammalian target
287–292
Ras
1495–1496
activation of Raf
274–277
mitogenic insulin response
277
Ras-dependent signaling pathway
insulin
421–428
Ras-MAP kinase
424
Rat insulin II promoter (RIP)
612
Rat insulinoma protein
506
Rats
environmental factors
604
genetic variation in
604
phenotypic variation in
603–604
RCP lymphocytic choriomeningitis virus (LCMV)
manipulations of
614
RCR
749
Reactive hypoglycemia
1434
Reactive oxygen species (ROS)
714–716
1093
1317
1506
Receptor for advanced glycation end products (RAGE)
1317
1444
Receptor tyrosine kinases (RTK)
225
234
Regional metabolism
NMR
810
noninvasive imaging
809–811
810
PET
810
Regitine
1355
Regulated insulin gene expression
non-beta-cells
755–756
Relapse prevention
in obesity
851
Relative hypoleptinemia
147
Renal disease
1390–1391
protein
661–662
Renal failure
1430
Renin-angiotensin-aldosterone system
1377–1378
P.1536

Renin-angiotensin-aldosterone system (RAAS)
1504
diabetic vasculopathy
1505–1507
Renin-angiotensin system
insulin
1381
Reovirus
576
Repaglinide
1111
1116
1163
1221
characteristics of
1115
clinical pharmacology of
1165
hypoglycemia
1220
mechanism studies
1167–1168
safety and efficacy
1170–1174
Replication competent retroviruses (RCR)
749
Resistance syndrome
PPAR-gamma
445–446
Resistin
969
979
Resorption
of embryos
1255
Respiratory decompensation
in neonates
1282–1283
Respiratory distress syndrome
1283
Restriction fragment length polymorphism (RFLP)
541
1005
Retina
vasculature of
morphologic changes in
1469
Retinal detachment
672
Retinal hemorrhage
672
Retinoid X receptor ligands
PPAR-gamma
444–445
Retinopathy
650–651
651
1469–1474
angiostatin
1473
antiangiogenic factors
1473–1474
antiplatelet treatment
1309
aspirin
1309
capillary closure
1305
classification of
1304
cumulative incidence of
462
diabetic nephropathy
1474–1477
early
pathogenesis of
1308–1309
epidemiology of
1306–1307
FGF
1472–1473
HbA1C
650
HGF
1473
IGF-1
1471–1472
microaneurysms
1303–1304
morphologic changes
1469
natural course of
1303–1304
new vessels
1305
optic disc neovascularization
1305
1305
pathophysiology of
1303–1312
PDGF
1473
PEDF
1473
photocoagulation
1309–1310
PIGF
1473
pregnancy
1265–1269
1267
prevalence of
in type 2 diabetes mellitus
465
progression of
risk factors for
1307–1308
SERPIN
1473
severe visual loss
1306
TGF-beta
1473
type 1 diabetes mellitus
1267
vascular permeability
1304–1305
VEGF
1469–1471
vitreous and fibrovascular proliferation contraction
1306
Retrograde ejaculation
1355
Retroviral vectors
747–749
Retrovirus
576
type 1 diabetes mellitus
586
Retrovirus diabetes
nonobese diabetic mice
580
Reverse Randle cycle
994–996
Reversible tyrosine phosphorylation
in insulin signaling
255
RFLP
541
1005
Rhabdomyolysis
1372
Rheologic agents
diabetic neuropathy
1352
Rhesus monkeys
beta 3 adrenergic receptors
1071
Rheumatoid arthritis
501
Riopan
1354
RIP
612
RIPE-3b1 activator
132
Risperidone
884
Rodent genetic models
of obesity
1041–1053
of type 2 diabetes mellitus
1041–1053
Rodent hypertension
glucose transporters
922–923
Rodent strains
obesity
830
ROS See Reactive oxygen species (ROS)
Rosiglitazone
148
444
1144–1145
1147
hypoglycemia
1220
Rotavirus
576
586
RPTP alpha See Leukocyte antigen related phosphatase (LRP)
RTK
225
234
Rubella virus
576
diabetes mellitus
hamsters
582
rabbits
582
type 1 diabetes mellitus
584–585
Ryanodine receptors (RyR)
61
←↑→